| PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer KD Gray, JE McCloskey, Y Vedvyas, OR Kalloo, SE Eshaky, Y Yang, ... Clinical Cancer Research 26 (22), 6003-6016, 2020 | 35 | 2020 |
| Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro TM Ullmann, H Liang, MD Moore, I Al-Jamed, KD Gray, J Limberg, ... Surgery 167 (1), 56-63, 2020 | 26 | 2020 |
| Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma J Limberg, CE Egan, KD Gray, M Singh, Z Loewenstein, Y Yang, ... Molecular Cancer Research 21 (5), 397-410, 2023 | 8 | 2023 |
| CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules W Li, S Xia, A Aronova, IM Min, A Verma, T Scognamiglio, KD Gray, ... Journal of Surgical Oncology 118 (6), 1042-1049, 2018 | 6 | 2018 |
| Exposure to polybrominated diphenyl ether flame retardants causes deoxyribonucleic acid damage in human thyroid cells in vitro TM Ullmann, H Liang, H Mora, J Greenberg, KD Gray, J Limberg, ... Journal of Surgical Research 279, 77-83, 2022 | 5 | 2022 |
| PRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis H Liang, ML Fisher, C Wu, C Ballon, X Sun, AA Mills Cancers 16 (22), 3789, 2024 | | 2024 |
| The role of the IFNγ pathway in the development of vemurafenib resistance in BRAFV600E mutant thyroid carcinoma J Limberg, KD Gray, M Singh, TM Ullmann, B Wyrwas, W Wang, ... Cancer Research 80 (16_Supplement), 1895-1895, 2020 | | 2020 |
